Parkland Health and Hospital Systems
Dallas, Texas, 75235, United States
NCT Number: NCT03407625
Induction of labor is associated with increased cesarean delivery rates, particularly in women with an unfavorable cervix. Both pharmacologic and mechanical methods are utilized for cervical ripening and labor induction. Evidence on the safety and effectiveness of various mechanical and pharmacologic methods of cervical ripening and labor induction is abundant, and yet the majority of clinical trials evaluate time to delivery, rather than mode of delivery. This is a prospective, cluster-randomized clinical trial to compare a standard method of induction at our institution (oral misoprostol) with an alternative, commonly used combination method of oral misoprostol and transcervical foley bulb in women with term pregnancies requiring induction of labor.
Looking for future studies?
Notify Me10 year and older
Female
Interventional
Not applicable
Dallas, Texas, 75235, United States
The purpose of this study is to determine whether the use of a transcervical foley catheter, in combination with the standard oral misoprostol regimen will result in a decreased primary cesarean delivery rate among women with a cervical dilation of 2 centimeters of less who require induction of labor at term. This study is not an FDA-regulated study: there is no intent to test the foley bulb under an FDA-regulated protocol. Likewise, there is no intent to submit the results of this study for a change in the labeling of the foley used for this study. This study was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center, and by the Office of Research Administration at Parkland Health and Hospital System.
This will be a prospective, cluster-randomized trial comparing two accepted methods of induction of labor at term among women who present for delivery at Parkland Hospital. Eligible participants will include nulliparous and multiparous women at 37 weeks gestation or greater, with a living, singleton fetus and no major fetal malformations, in cephalic presentation, with intact membranes, no prior uterine scar, who qualify for prostaglandin administration and who have a cervical dilation of 2 centimeters or less, measured at the level of the internal os. Patients with latex allergy, non-reassuring fetal status, HIV, active herpes outbreak, a prior uterine scar, or any contraindication to prostaglandins (including 4 or more painful contractions per 10 minutes prior to prostaglandin administration) will be excluded from participation in the study.
Computer-generated cluster randomization will occur on a weekly basis for all study participants, to either the combination method of foley bulb plus oral misoprostol regimen (study group) or to oral misoprostol alone regimen (control).
According to the randomization protocol each week, participants will be randomized to either the standard of care (oral misoprostol/control group) or standard of care plus foley bulb (study group). The study group will undergo placement of a 30 French foley catheter filled with 30-35cc sterile saline into the cervix in addition to the standard regimen of oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses, for patients who meet criteria for fetal well-being, and do not had more than 4 painful contractions in 10 minutes. Misoprostol will not be administered to patients who have progressed to active labor, defined as 4 centimeters cervical dilation. The control group will undergo induction with our current standard oral misoprostol protocol alone, administered as 100 micrograms given every 4 hours for a maximum of 2 doses. Both groups will receive oxytocin as indicated by current labor protocols at our institution.
The primary outcome will be the rate of vaginal delivery. Secondary outcomes will include obstetric outcomes, maternal outcomes, and neonatal outcomes. Obstetric outcomes will include indication for induction, need for oxytocin, indication for cesarean delivery, time to active labor, time to delivery, labor analgesia, presence of chorioamnionitis, meconium-stained amniotic fluid, terbutaline use, tachysystole (defined as 6 or more contractions in 10 minutes or tetanic contraction of 120 seconds or longer) or hyperstimulation syndrome (defined as tachysystole accompanied by fetal heart rate decelerations). Maternal outcomes will include estimated blood loss, transfusion requirement, postpartum fever, uterine rupture, and unplanned hysterectomy. Neonatal outcomes will include umbilical cord blood pH, 5-minute APGAR score, intubation or ventilation in the delivery room, neonatal sepsis, and admission to Neonatal Intensive Care Unit (NICU) admission.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Although labeled "experimental" for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.
Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
Time frame: at delivery
vaginal delivery at first induction
Time frame: from start of induction agent to time of delivery
Time (in hours) from start of induction agent to delivery at first induction
Time frame: at delivery
Among women delivered by cesarean, the indication for cesarean
Time frame: at delivery
Total dose of oxytocin given for induction as calculated by volume infused, concentration of solution and rate of infusion
Time frame: From time of documented insertion until the time of documented expulsion or removal, whichever came first, assessed up to 24 hours.
time (in hours) from insertion to removal or expulsion of foley bulb
Time frame: at delivery
Intrapartum fever (temp equal or greater than 38C) with no other identified cause
Time frame: at delivery
Intravenous analgesia used between the start of induction and delivery
Time frame: from start of induction to delivery
Regional or neuraxial analgesia (labor epidural or spinal) used between the start of induction and delivery
Time frame: at delivery
General anesthesia administered for delivery
Time frame: At the time of rupture of membranes and at delivery
Identification of any meconium (green tinge) in the amniotic fluid before or during delivery by a healthcare provider's assessment of gross fluid color.
Time frame: at delivery
Administration of terbutaline, a tocolytic agent, for tetanic contractions with or without fetal heart rate decelerations
Time frame: at delivery
6 or more contractions in 10 minutes or tetanic contraction of 120 seconds or longer
Time frame: at delivery
Tachysystole accompanied by fetal heart rate decelerations
Time frame: at delivery
Maternal excess blood loss is defined as >500ml for vaginal and >1000ml for cesarean delivery
Time frame: at delivery
administration of blood products related to delivery blood loss
Time frame: at delivery
spontaneous separation of myometrium in a previously intact, unscarred uterus
Time frame: at discharge from the hospital following delivery
unplanned removal of the uterus following delivery of the fetus
Time frame: Following delivery and prior to discharge
Fever recorded in the time after delivery but prior to discharge from the hospital, with clinical assessment of endometritis
Time frame: at delivery
Arterial or venous cord blood pH defined as <7.0
Time frame: 5 minutes after time of birth
Appearance, Pulse, Grimace, Activity, Respirations - scored from 0 to 2 for each component, added to make a total score and used as an assessment of initial response to newborn resuscitation, lower scores associated with poor outcomes. Here defined as Apgar less than 4 at 5 minutes.
Time frame: at delivery
Intubation with mechanical support or control of neonatal breathing in delivery room
Time frame: From time of birth until the time of discharge or up to 7 days of life, whichever comes first.
Administration of neonatal antibiotics and/or neonatal blood cultures
Time frame: From time of birth until the time of discharge or up to 7 days of life, whichever comes first.
Neonatal bacteremia as defined by bacterial growth in blood cultures
Time frame: From time of birth until the time of discharge or up to 7 days of life, whichever comes first.
Admission order to neonatal intensive care unit (NICU) placed between the time of delivery and infant discharge
University of Texas Southwestern Medical Center
Other
Foley Bulb With Oral Misoprostol Versus Oral Misoprostol for Induction of Labor: A Cluster Randomized Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04755218
Labor, Induced, Pregnancy
Dallas, Texas, United States
View Trial DetailsNCT01962831
Body Weight, Labor, Induced
Regina, Saskatchewan, Canada
View Trial DetailsNCT00465998
Labor, Induced, Pregnancy
Stavanger, Norway
View Trial DetailsNCT07272785
Childbirth Experience, Humans
Turku, Finland
View Trial Details